Mitomycin C plus S-1 as second-line therapy in patients with advanced gastric cancer: a noncomparative phase II study-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Mitomycin C plus S-1 as second-line therapy in patients with advanced gastric cancer: a noncomparative phase II study

Published:2008-03 Issue:3 Volume:19 Page:303-307
ISSN:0959-4973
Container-title:Anti-Cancer Drugs
language:en
Short-container-title:

Author:

Park Se Hoon,Kim Young Saing,Hong Junshik,Park Jinny,Nam Eunmi,Cho Eun Kyung,Shin Dong Bok,Lee Jae Hoon,Lee Woon Kee,Chung Min

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Cancer Research,Pharmacology (medical),Pharmacology,Oncology

Reference29 articles.

1. Annual report of the Korean central cancer registry program 2000;Bae;Cancer Res Treat,2002

2. Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer;Pyrhonen;Br J Cancer,1995

3. Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer;Glimelius;Ann Oncol,1997

4. The role of chemotherapy in the current treatment of gastric cancer;Van Cutsem;Gastric Cancer,2002

5. Phase II study of S-1, a novel oral derivative of 5-fluorouracil, in advanced gastric cancer. For the S-1 Cooperative Gastric Cancer Study Group;Koizumi;Oncology,2000

Cited by 30 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Definitive S-1/mitomycin-C chemoradiotherapy for stage II/III anal canal squamous cell carcinoma: a phase I/II dose-finding and single-arm confirmatory study (JCOG0903);International Journal of Clinical Oncology;2023-06-07

2. Immune-Related Protein Interaction Network in Severe COVID-19 Patients toward the Identification of Key Proteins and Drug Repurposing;Biomolecules;2022-05-11

3. Apatinib: A novel receptor tyrosine kinase inhibitor for the treatment of gastric cancer;Cancer Letters;2016-03

4. Second-Line Treatment of Advanced Gastric Cancer: Where Do We Stand?;Journal of the National Comprehensive Cancer Network;2015-10

5. Progression-free survival as a surrogate endpoint for overall survival in patients with third-line or later-line chemotherapy for advanced gastric cancer;ONCOTARGETS THER;2015

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3